参考文献/References:
[1] Bootcov MR,Bauskin AR,Valenzuela SM,et al. MIC-1,a novel macrophage inhibitory cytokine,is a divergent member of the TGF-beta superfamily[J]. Proc Natl Acad Sci U S A,1997,94(21):11514-11519.
[2] Unsicker K,Spittau B,Krieglstein K. The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1[J]. Cytokine Growth Factor Rev,2013,24(4):373-384.
[3] B?ttner M,Laaff M,Schechinger B,et al. Characterization of the rat,mouse,and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1)[J]. Gene,1999,237(1):105-111.
[4] Patel S,Alvarez-Guaita A,Melvin A,et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans[J]. Cell Metab,2019,29(3):707-718.e8.
[5] Day EA,Ford RJ,Smith BK,et al. Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss[J]. Nat Metab,2019,1(12):1202-1208.
[6] Sen T,Li J,Neuen BL,et al. Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin:results from the CANVAS trial[J]. J Am Heart Assoc,2021,10(23):e021661.
[7] Wallentin L,Hijazi Z,Andersson U,et al. Growth differentiation factor 15,a marker of oxidative stress and inflammation,for risk assessment in patients with atrial fibrillation:insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial[J]. Circulation,2014,130(21):1847-1858.
[8] Hylek EM,Held C,Alexander JH,et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin:The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation):Predictors,Characteristics,and Clinical Outcomes[J]. J Am Coll Cardiol,2014,63(20):2141-2147.
[9] Siegbahn A,Lindback J,Hijazi Z,et al. Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation[J]. J Thromb Haemost,2021,19(11):2726-2737.
[10] Hijazi Z,Oldgren J,Andersson U,et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation:Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[J]. Am Heart J,2017,190:94-103.
[11] Hijazi Z,Oldgren J,Lindb?ck J,et al. The novel biomarker-based ABC (age,biomarkers,clinical history)-bleeding risk score for patients with atrial fibrillation:a derivation and validation study[J]. Lancet,2016,387(10035):2302-2311.
[12] Berg DD,Ruff CT,Jarolim P,et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48[J]. Circulation,2019,139(6):760-771.
[13] Benz AP,Hijazi Z,Lindb?ck J,et al. Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation[J]. Circulation,2021,143(19):1863-1873.
[14] Hijazi Z,Oldgren J,Lindb?ck J,et al. Evaluation of the age,biomarkers,and clinical history-bleeding risk score in patients with atrial fibrillation with combined aspirin and anticoagulation therapy enrolled in the ARISTOTLE and RE-LY Trials[J]. JAMA Netw Open,2020,3(9):e2015943.
[15] 柯于梵,钟桃娟,萧湛潮,等. 血清生长分化因子15及ABC出血风险评分在预测老年非瓣膜病心房颤动患者口服非维生素K拮抗剂抗凝药出血风险的临床应用初探[J]. 中国动脉硬化杂志,2022,30(5):423-430.
[16] Skowrońska M,Skrzyńska M,Machowski M,et al. Plasma growth differentiation factor 15 levels for predicting serious adverse events and bleeding in acute pulmonary embolism:a prospective observational study[J]. Pol Arch Intern Med,2020,130(9):757-765.
[17] Pol T,Hijazi Z,Lindback J,et al. Evaluation of the prognostic value of GDF-15,ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas[J]. Open Heart,2021,8(1):e001471.
[18] Sharma A,Hijazi Z,Andersson U,et al. Use of biomarkers to predict specific causes of death in patients with atrial fibrillation[J]. Circulation,2018,138(16):1666-1676.
[19] Hagstrom E,James SK,Bertilsson M,et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes:results from the PLATO study[J]. Eur Heart J,2016,37(16):1325-1333.
[20] Lindholm D,Hagstrom E,James SK,et al. Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding[J]. J Am Heart Assoc,2017,6(4):e005580.
[21] Lindholm D,James SK,Gabrysch K,et al. Association of multiple biomarkers with risk of all-cause and cause-specific mortality after acute coronary syndromes:a secondary analysis of the PLATO biomarker study[J]. JAMA Cardiol,2018,3(12):1160-1166.
[22] Farhan S,Freynhofer MK,Brozovic I,et al. Determinants of growth differentiation factor 15 in patients with stable and acute coronary artery disease. A prospective observational study[J]. Cardiovasc Diabetol,2016,15:60.
[23] Kazem N,Hammer A,Koller L,et al. The prognostic potential of growth differentiation factor-15 on bleeding events and patient outcome after cardiac surgery-a prospective cohort study[J]. Thromb Haemost,2022,122(5):703-714.
[24] Sluka M,Hutyra M,Nykl R,et al. Risk stratification using growth differentiation factor 15 in patients undergoing transcatheter aortic valve implantation[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2022 Apr 12.?DOI: 10.5507/bp.2022.017.?Online ahead of print.
[25] Song L,S?derholm M,Svensson EH,et al. Circulating growth differentiation factor 15 levels are associated with risk of both intracerebral and subarachnoid hemorrhage[J]. Front Neurol,2021,12:664010.
[26] Mulder FI,Boschf TM,Carrier M,et al. Growth differentiation factor-15 for prediction of bleeding in cancer patients[J]. J Thromb Haemost,2022,20(1):138-144.
[27] Ioannou A,Papageorgiou N,Falconer D,et al. Biomarkers associated with stroke risk in atrial fibrillation[J]. Curr Med Chem,2019,26(5):803-823.
[28] Wischhusen J,Melero I,Fridman WH. Growth/differentiation factor-15 (GDF-15):from biomarker to novel targetable immune checkpoint[J]. Front Immunol,2020,11:951.
[29] Eggers KM,Lindahl B. Prognostic biomarkers in acute coronary syndromes:risk stratification beyond cardiac troponins[J]. Curr Cardiol Rep,2017,19(4):29.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(10):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(10):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(10):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(10):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(10):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(10):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
[11]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(10):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]